EQRX Overzicht aandelen
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
EQRx, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.34 |
| 52 Week Hoogtepunt | US$3.96 |
| 52 Week Laag | US$1.58 |
| Bèta | 0.48 |
| 11 maand verandering | 5.41% |
| 3 maanden verandering | 4.46% |
| 1 Jaar Verandering | -36.24% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -76.79% |
Recent nieuws en updates
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24Rendement voor aandeelhouders
| EQRX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -5.3% | -0.7% | -1.6% |
| 1Y | -36.2% | 19.8% | 30.8% |
Rendement versus industrie: EQRX underperformed the US Biotechs industry which returned -4.2% over the past year.
Rendement versus markt: EQRX underperformed the US Market which returned 14.1% over the past year.
Prijsvolatiliteit
| EQRX volatility | |
|---|---|
| EQRX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: EQRX has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: EQRX's weekly volatility (5%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2019 | 362 | Melanie Nallicheri | www.eqrx.com |
EQRx, Inc. Samenvatting
| EQRX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.14b |
| Inkomsten(TTM) | -US$260.31m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-4.4x
Koers/WinstverhoudingIs EQRX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EQRX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$260.32m |
| Inkomsten | -US$260.31m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.54 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde EQRX op de lange termijn?
Bekijk historische prestaties en vergelijking